GLP‑1 AE patterns emerge
Real‑world pharmacovigilance analysis is showing clustered adverse events for GLP‑1 receptor agonists across metabolic, nutritional, gastrointestinal and psychiatric categories as use expands. Clinicians and safety teams are being urged to watch for longer‑term, unexpected effects as prescribing grows. (x.com)
Glucagon-like peptide-1 drugs slow stomach emptying and curb appetite, and newer safety analyses are finding adverse-event patterns that cluster across several body systems. (frontiersin.org) In one 2024 pharmacovigilance study using the Food and Drug Administration Adverse Event Reporting System through the second quarter of 2023, researchers found 10,450 metabolism-and-nutrition reports for exenatide, 4,847 for dulaglutide, 2,905 for semaglutide, and 1,089 for tirzepatide. (pubmed.ncbi.nlm.nih.gov) That same study found semaglutide, liraglutide, and exenatide had stronger reporting signals for metabolic and nutritional problems, while dehydration was the most frequent serious-outcome event for liraglutide, dulaglutide, semaglutide, and tirzepatide. (pubmed.ncbi.nlm.nih.gov) A separate 2024 analysis of psychiatric reports in the same Food and Drug Administration database reviewed 8,240 psychiatric cases out of 181,238 total adverse-event reports linked to glucagon-like peptide-1 receptor agonists from 2004 through the first quarter of 2023. (frontiersin.org) The psychiatric study found a median onset of 31 days and identified reporting signals for nervousness, stress, eating disorder, insomnia-type sleep disorder, binge eating, fear of eating, and self-induced vomiting. (frontiersin.org) A 2025 Scientific Reports paper widened the picture again, identifying 28,953 neurological adverse-event reports tied to six drugs in the class and 19 distinct signals, including dizziness, tremor, lethargy, taste disorder, and hypoglycemic unconsciousness. (nature.com) These studies rely on spontaneous reports, which work like an early-warning radar rather than a final verdict. The Food and Drug Administration says a report in its database does not mean the drug caused the event, because the system is affected by underreporting, duplicate reports, and missing clinical detail. (fda.gov) The signal hunting is getting more attention as use rises. A Centers for Disease Control and Prevention data brief published in July 2025 said 26.3% of U.S. adults with diagnosed diabetes were taking an injectable glucagon-like peptide-1 medication in 2024. (cdc.gov) Known side effects are already built into product labels. The current semaglutide label says the drug delays gastric emptying, and Wegovy lists nausea, vomiting, diarrhea, constipation, and abdominal pain among common adverse reactions. (accessdata.fda.gov; wegovy.com) Regulators have also been narrowing some concerns as more data come in. On January 13, 2026, the Food and Drug Administration said it was asking manufacturers to remove suicidal-behavior and suicidal-ideation warnings from certain glucagon-like peptide-1 obesity drugs after its review did not find evidence of increased risk. (fda.gov) The immediate takeaway for clinicians is not that every signal will prove causal, but that broader prescribing is producing a larger map of what to watch: dehydration, gastrointestinal complications, and less-expected neurologic or psychiatric reports that may appear within the first month. (pubmed.ncbi.nlm.nih.gov; frontiersin.org; nature.com)
